Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AndroScience Corp
Subjects with acne were randomized to one of four treatment groups for twice daily topical dosing to the face for 12 weeks. Assessments of acne status were performed at Baseline, Weeks 2, 4, 8 and 12 and then 4 weeks after the last dose of study drug.
Age
12–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
At least 12 years of age.
Facial acne, with:
20 -100 inflammatory facial lesions 20 -100 noninflammatory facial lesions No more than 2 nodules/cysts on the face
You may not be if
Women who are pregnant or breastfeeding
Skin diseases other than acne vulgaris
Use of oral retinoids within 6 months of Baseline Visit
Unwilling to discontinue all other treatments for facial acne
Unwilling to avoid excessive swimming/sun exposure and use of cosmetics
Clareo Health | A Phase 2 Study of ASC-J9 Cream in Acne Vulgaris
